Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA (2023 - 2025)

Historic EBITDA for Camp4 Therapeutics (CAMP) over the last 3 years, with Q3 2025 value amounting to -$15.1 million.

  • Camp4 Therapeutics' EBITDA fell 1197.72% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year decrease of 368.14%. This contributed to the annual value of -$51.8 million for FY2024, which is 507.19% down from last year.
  • According to the latest figures from Q3 2025, Camp4 Therapeutics' EBITDA is -$15.1 million, which was down 1197.72% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' EBITDA registered a high of -$11.7 million during Q3 2023, and its lowest value of -$15.1 million during Q3 2025.
  • For the 3-year period, Camp4 Therapeutics' EBITDA averaged around -$13.0 million, with its median value being -$12.6 million (2025).
  • Per our database at Business Quant, Camp4 Therapeutics' EBITDA crashed by 1528.73% in 2024 and then rose by 15.26% in 2025.
  • Quarter analysis of 3 years shows Camp4 Therapeutics' EBITDA stood at -$13.0 million in 2023, then fell by 2.22% to -$13.3 million in 2024, then decreased by 13.71% to -$15.1 million in 2025.
  • Its EBITDA was -$15.1 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$12.4 million in Q1 2025.